vimarsana.com

Page 4 - சிட்னி கீம்மேல் விரிவான புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

2 drugs may boost brain cancer treatment for kids

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Share: Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer MIAMI, May 24, 2021 (GLOBE NEWSWIRE) Veru Inc. (NASDAQ:VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that two abstracts were accepted for presentation at the 2021 American Society of Clinical Oncology Annual Meeting which will be held virtually from June 4-8, 2021.

Novel Immunotherapy Boosts Melanoma Outcomes

email article A dual immunotherapy regimen targeting the novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma, according to a phase III study. At a median follow-up of 13.2 months, the combination of the anti-LAG-3 antibody relatlimab and the PD-1 inhibitor nivolumab (Opdivo) extended PFS to 10.1 months, as compared with 4.6 months with nivolumab alone (HR 0.75, 95% CI 0.6-0.9, P=0.0055), reported Evan Lipson, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Relatlimab and nivolumab is a potential novel treatment option for this patient population, said Lipson during a press briefing held in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.